B Cell Lymphoma
News
Prognostic gene signature identifies high- vs. low-risk DLBCL patients
The researchers calculated risk scores using their prognostic gene set in three additional published DLBCL studies.
News
FDA okays new CAR T-cell treatment for large B-cell lymphomas
News
Concern over response to COVID-19 in patients with blood cancers
Conference Coverage
Four-item prognostic index predicts survival in adult Burkitt lymphoma
Conference Coverage
Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies
Conference Coverage
ZUMA-12 study shows frontline axi-cel has substantial activity in high-risk large B-cell lymphoma
Conference Coverage
Pediatric regimens better for adolescents/young adults with aggressive B-cell NHL
Conference Coverage
Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL
Conference Coverage
ZUMA-5: Axi-cel yields high response rate in indolent NHL
The CAR T-cell therapy had a favorable safety profile and a median duration of response that had not been reached at a median of 17.5 months...
Conference Coverage
COVID-19–related outcomes poor for patients with hematologic disease in ASH registry